Daewoong Pharmaceutical "Botulinum Toxin 'Nabota' Effective for Male Pattern Hair Loss"

[Asia Economy Reporter Hyun-ui Cho] Daewoong Pharmaceutical announced on the 25th that it has confirmed the efficacy of the botulinum toxin formulation 'Nabota' in treating male pattern baldness.

Professor Byung-chul Park's dermatology team at Dankook University set approximately 20 injection sites on the bald area to verify the efficacy and safety of botulinum toxin in male pattern baldness, administering Nabota six times at 4-week intervals. Each injection consisted of 30 units (U), totaling 180 units (U) over 24 weeks.

As a result, the number of hairs significantly increased at week 24 compared to before treatment. Visual assessments by the researchers also showed improvement in hair loss. No serious drug-related adverse events were reported.

In previous studies, Professor Park confirmed that Nabota induces the telogen phase in hair follicle cells and suppresses the secretion of TGF-β1, which causes hair loss. He explained, "By injecting botulinum toxin into the dermal hair follicles, TGF-β1 is suppressed, which appears to extend the anagen phase of hair growth, inhibit telogen hair shedding, reduce hair loss, and increase hair volume."

The results of this study will be published in the December issue of the SCI journal 'Journal of the American Academy of Dermatology' (JAAD).

Professor Park's team is currently conducting a Phase 2b clinical trial to verify an effective and convenient administration method by extending the Nabota injection interval to three months and increasing the dose per follicle injection in patients with male pattern baldness.